Genomic Testing in Women with Early-Stage Hormone Receptor–Positive, HER2-Negative Breast Cancer
Author and Disclosure Information [Show]

Sima Ehsani, MD
Assistant Professor of Medicine, Division of Hematology/Medical Oncology, University of Arizona Cancer Center, Tucson, AZ

Kari Braun Wisinski, MD
Associate Professor, Department of Medicine, University of Wisconsin Carbone Cancer Center, Madison, WI

Question 1 of 5

A 48-year-old premenopausal woman presents with a mammogram-detected right breast invasive ductal carcinoma (IDC), grade II, positive for both estrogen and progesterone receptors (ER and PR) and HER2-negative. Ki-67 is 15%. She undergoes a partial mastectomy and sentinel lymph node biopsy (SLNB), with pathology showing a 2.1-cm tumor, no lymphovascular invasion, negative margins, and 1 out of 2 SLNs positive for metastasis. Complete blood count and comprehensive metabolic panel are unremarkable.

Which of the following tests will help estimate this patient’s risk for distant breast cancer recurrence?

A baseline serum CA 27-29

Ki-67 assay

21-gene assay (Oncotype DX)

None of the above, as the prognostic value of genomic tests has not been validated in node-positive breast cancers

Hospital Physician: Hematology/Oncology. 2017 November;12(6)

This quiz is not accredited for CME.

More from Board Review Questions: Hematology/Oncology

QUIZ

Management of Advanced Melanoma
Castration-Resistant Prostate Cancer
Transfusion Reactions (part 2)
Transfusion Reactions (part 1)
Plasma Cell Disorders (part 3)
Plasma Cell Disorders (part 2)
Chronic Myeloid Leukemia
Aplastic Anemia
Small Cell Lung Cancer
Management of Metastatic Gastric Cancer
Transfusion Medicine
Management of Colorectal Cancer in Older Adults
Urothelial Carcinoma: Muscle-Invasive and Metastatic Disease
Acute Myeloid Leukemia
Aggressive B-Cell Non-Hodgkin Lymphoma
Pancreatic Adenocarcinoma: Advanced Unresectable and Metastatic Disease
HER2-Positive Breast Cancer
Von Willebrand Disease: Assessment and Diagnostic Testing
Von Willebrand Disease: Clinical Management
Pancreatic Adenocarcinoma: Neoadjuvant and Adjuvant Treatment
Late Pulmonary Complications After Hematopoietic Stem Cell Transplantation
Polycythemia Vera and Essential Thrombocythemia: Current Management
Treatment of Biliary Tract Cancers
Early Pulmonary Complications After Hematopoietic Stem Cell Transplantation
Hairy Cell Leukemia
Immune Thrombocytopenia
Cancer-Related Fatigue
Disseminated Intravascular Coagulation
Advanced Stage and Relapsed/Refractory Hodgkin Lymphoma
Adjuvant Chemotherapy for Colon Cancer
Molecular Markers and Targeted Therapies in the Management of Non-Small Cell Lung Cancer
Metastatic Cutaneous Melanoma: Targeted Therapy and Immunotherapy
Thrombosis in Pregnancy
Locally Advanced Pancreatic Cancer
Early-Stage Hodgkin Lymphoma
Neoadjuvant and Adjuvant Therapy for Gastric Cancer
Hemophilia A and B
Mantle Cell Lymphoma
Soft Tissue Sarcoma
Sickle Cell Disease
Renal Cell Carcinoma
Management of Locally Advanced Rectal Adenocarcinoma
Adjuvant Systemic Therapy for Early-Stage Breast Cancer
Chronic Myeloid Leukemia
Plasma Cell Disorders
Myelodysplastic Syndromes
Acute and Chronic Graft-versus-Host Disease